Global Nucleic Acid Sample Preparation Industry Research 2023-2033: Emergence of Advanced Stabilization Products, Regulated vs. Multimodal Analysis, Exploring New Applications

The global nucleic acid sample preparation market is projected to reach $5,615.9 million by 2033 from $2,922.8 million in 2023, growing at a CAGR of 6.75% during the forecast period 2023-2033

The base year considered for the calculation of the nucleic acid sample preparation market size is 2022. A historical year analysis has been done for the period FY2020-FY2021. The nucleic acid sample preparation market size has been estimated for FY2022 and projected for the period FY2023-FY2033.

The key factors driving the growth of the global nucleic acid sample preparation market include the growth in the number of genetic tests globally and an increase in demand for reliable next-generation sequencing (NGS) platforms in clinical laboratories. The rapid growth of genomic research has resulted in an increasing need for the storage of biologic samples, including DNA and RNA. Stabilization products enable researchers to transport and store biological samples for long periods with complete and rapid sample recovery at affordable costs.

These products are used to retain biological materials at room temperature without degradation. These stabilization products ensure that the nucleic material, which has been carefully purified, remains safe and ready for further downstream applications, such as ensuring accurate gene expression analysis through qPCR or QRT-PCR. Research studies suggest that cell lysates created using lysis and stabilization buffers observed no shift in Ct value versus fresh samples, indicating that the nucleic acid was stable and intact while stored in these stabilization solutions.

In order to cross-examine biological samples for changes in DNA and RNA efficiently, there have been considerable advances in NGS chemistries, platforms, and bioinformatics pipelines. Currently, the regulated approach requires the use of two separate workflows for library preparation from separate DNA and RNA isolates. The regulated analysis approach presents certain limitations, such as the large amounts of sample required for generating sufficient nucleic acid for multiple workflows, inefficient use of resources, and long turn-around times.

China dominated the Asia-Pacific nucleic acid sample preparation market in 2022. China has maintained itself as an attractive market for life sciences solution providers capable of tapping the strong demand for nucleic acid extraction products. Several companies, including Qiagen, Thermo Fisher Scientific, BioTeke, Promega, F. Hoffmann-La Roche AG, and Takara Bio, are the leading suppliers of nucleic acid extraction consumables in the country. The Chinese government recognizes the potential of nucleic acid sample preparation and is actively promoting its development and manufacturing.

Revenues of the companies have been referenced from their annual reports for FY2020-FY2022. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, product approval status, market collaborations, and operational history.

Market Segmentation Highlights

  • Based on product, the nucleic acid sample preparation market has been led by consumables, which held a 67.83% share in 2022.
  • Based on consumables market by type, the nucleic acid sample preparation market has been led by Kits, which held a 87.65% share in 2022.
  • Based on nucleic acid sample preparation consumables market Kits by Type, the nucleic acid sample preparation market has been led by DNA/RNA Sample Isolation/Extraxtion/Purification, which held an 83.93% share in 2022.
  • Based on consumables market by analyte, the nucleic acid sample preparation market has been led by DNA, which held a 64.57% share in 2022.
  • Based on consumable-based technology, the nucleic acid sample preparation consumable market has been led by silica-based technology, which held a 48.58% share in 2022.
  • Based on instrument-based technology, the nucleic acid sample preparation instrument market has been led by magnetic bead-based, which held a 58.72% share in 2022.
  • Based on application, the nucleic acid sample preparation market has been led by qPCR, which held a 31.87% share in 2022.
  • Based on end user, the nucleic acid sample preparation market has been led by academic research institutes and laboratories, which held a 45.95% share in 2022.

Key Attributes:

Report Attribute Details
No. of Pages 265
Forecast Period 2023 – 2033
Estimated Market Value (USD) in 2023 $2922.8 Million
Forecasted Market Value (USD) by 2033 $5615.9 Million
Compound Annual Growth Rate 6.7%
Regions Covered Global

Key Topics Covered:

Market Drivers

  • Growing Number of Genetic Tests
  • Increasing Demand for Reliable Next-Generation Sequencing (NGS) Platforms in Clinical Laboratories
  • Increasing Prevalence of Infectious Diseases and Cancer Cases
  • Rise in the Field of Microbial Sequencing
  • Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
  • Decreasing Cost of Sequencing

Market Restraints

  • Genomic Data Protection
  • High Cost of Automated Instruments
  • Rigid Regulatory Standards

Market Opportunities

  • Development and Utilization of More Biobanks in Healthcare Segment
  • Technological Advancements in DNA/RNA Sample Preparation Processes
  • Growth in Emerging Nations
  • Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets

Key Developments

  • Product Launches and Approvals
  • Collaborations and Agreements
  • Acquisitions
  • Business Expansions

Industry Trends

  • Emergence of Advanced Stabilization Products
  • Regulated vs. Multimodal Analysis
  • Exploring New Applications
  • Other Key Trends

Definition by Products

  • Instruments
  • Column-Based Instruments
  • Bead-Based Instruments
  • Low-Throughput Instruments
  • Medium-Throughput Instruments
  • High-Throughput Instruments
  • Kits
  • Reagents

Nucleic Acid Sample Preparation Automation Applications

  • Genomic/Plasmid DNA Extraction
  • Cell-Free DNA (cfDNA) Extraction
  • Viral RNA Extraction
  • Cell-Free RNA Extraction

Company Profiles: Company Overview, Role in the Global Nucleic Acid Sample Preparation Market, Financials, Analyst Perspective

  • Agilent Technologies, Inc.
  • Autogen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Merck KGaA
  • Macherey-Nagel GmbH & Co KG
  • New England Biolabs, Inc.
  • Norgen Biotek Corp.
  • Omega Bio-tek, Inc.
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Promega Corporation
  • QIAGEN N.V.
  • Sage Science, Inc.
  • Tecan Group
  • Thermo Fisher Scientific Inc.
  • Zymo Research

For more information about this report visit here.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.